The magnitude of insider selling by two major holders (RA Capital and Third Rock) is unusually large relative to market cap and signals potential lack of confidence in near-term catalysts. Monitor for further insider sales or a potential secondary offering. The narrowed loss and cash runway are positive but do not offset the selling pressure from informed holders.
Drugs in focus
SEPN drug pipeline →SEP-479
● Neutral Named in this insider cluster- Impact
- Phase
- Phase 1
- Time to market
- If Phase 1 data are positive, SEP-479 would still need to complete Phase 2 and Phase 3 trials before any potential FDA submission, placing a potential approval several years away (likely 2029-2031 at the earliest).
- Next catalyst
- None dated
What to watchThe next catalyst for SEP-479 is the Phase 1 topline safety, PK and PD data readout, guided for late 2026 or early 2027. Positive data would validate the oral small-molecule approach against an injectable standard of care (YORVIPATH) and could drive SEPN shares higher given the strong analyst consensus. Negative data (safety signals or poor PK/PD) would be a significant setback for Septerna's lead wholly-owned program.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 17 $44.20entry
- T+1 · 3mo ago −0.91%α −0.23% · $43.80
- T+5 · 3mo ago −8.33%α −7.14% · $40.52
- T+20 · 2mo ago −12.08%α −10.10% · $38.86
- T+60 · 6d ago +18.42%α +21.36% · $52.34
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Septerna insiders sold $40.2M in stock over a 7-day window, led by a $31.7M open-market sale by director/10% owner RA Capital Management at $42.50, and a $7.4M sale by Third Rock Ventures. President/COO Bhatt exercised options and sold $1.1M at $44.00. The sales follow Q2 earnings (net loss narrowed to $13.0M, $516.5M cash runway into 2029) and a strategic pipeline shift for SEP-631. The total sales represent ~12.4% of market cap, a highly material cluster dominated by two large holders reducing positions, which is bearish despite the cash runway and narrowed loss.
Key Financial Metrics
Key Facts
- RA Capital Management sold 746,500 shares at $42.50 for $31.73M
- Third Rock Ventures sold 147,059 shares at $50.27 for $7.39M
- President/COO Bhatt sold 25,000 shares at $44.00 for $1.10M after exercising options
- Total insider sales of $40.2M represent ~12.4% of Septerna's ~$324M market cap
- Q2 2026 net loss of $13.0M narrowed from $24.8M YoY; cash of $516.5M funds operations into 2029
- SEP-631 shifted from Phase 2b CSU study to signal-finding studies in mast cell diseases
Financial Impact
Insider sales of $40.2M represent ~12.4% of market cap; two large holders (RA Capital and Third Rock) sold significant positions
Risk Factors
- Further insider selling or secondary offering from remaining large holders
- SEP-479 Phase 1 data not expected until Q1 2027, limiting near-term catalysts
- Strategic pivot for SEP-631 introduces pipeline uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SEPN-1786775263080 |
Track record
24 reports on SEPN
6 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 12, 20263d ago 144 Neutral 3/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $41.67 −0.45% settles Nov 19
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $52.34 Now $41.67 +20.39% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
- Sep 10, 20269w ago Press Release Neutral 2/10 Entry $38.51 to $38.69 Now $41.67 +8.21% ▲ +0.47% +0.69% vs SPY
- Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $41.67 +13.39% ▲ +7.62% +8.83% vs SPY
- Aug 25, 202611w ago 8-K Neutral 3/10 Entry $41.30 to $37.68 Now $41.67 +0.90% ▼ −8.77% −8.23% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers